Longitudinal evaluation of endothelial markers in children and adolescents with familial hypercholesterolemia.
Journal
Acta bio-medica : Atenei Parmensis
ISSN: 2531-6745
Titre abrégé: Acta Biomed
Pays: Italy
ID NLM: 101295064
Informations de publication
Date de publication:
03 11 2021
03 11 2021
Historique:
received:
04
12
2020
accepted:
04
12
2020
entrez:
5
11
2021
pubmed:
6
11
2021
medline:
12
11
2021
Statut:
epublish
Résumé
Children with heterozygous familial hypercholesterolemia (heFH) are at risk of premature atherosclerosis. Aims of this study were: (a) to longitudinally evaluate the endothelial dysfunction, estimated through brachial flow mediated dilation (FMD), as first sign of subclinical atherogenesis in a group of children and adolescents affected by heFH in comparison to normo-lipidemic controls, and (b) to identify predictive factors influencing the endothelial function and its development in the same cohort of patients. This is a prospective, longitudinal and cross-sectional study. Physical examination, plasma lipid profile and brachial artery FMD were measured at baseline and after follow-up. At baseline, FMD did not differ between heFH children (n.24, median age 9.71) and controls (n. 24, median age 10.29) (7.67 ± 9.26 vs. 11.18 ± 7.28 %, p 0.09). Nevertheless, during follow-up (median length of lipid-lowering diet 4.52 years), FMD got worse in 54% of heFH subjects and its worsening correlated to the increasing of low-density lipoprotein cholesterol (r -0.21, p < 0.05). Moreover, being male (β -0.46, p 0.03), undergoing puberty (β -0.61, p 0.03) and increasing of body mass index standard deviation score (β -0.39, p 0.03) were identified as main independent predictor factors of FMD drop. During the first decades of life, not only hypercholesterolemia, but also clusters of pro-atherogenic conditions and their persistence, could affect the endothelial function and its trend. (www.actabiomedica.it).
Sections du résumé
BACKGROUND AND AIM
Children with heterozygous familial hypercholesterolemia (heFH) are at risk of premature atherosclerosis. Aims of this study were: (a) to longitudinally evaluate the endothelial dysfunction, estimated through brachial flow mediated dilation (FMD), as first sign of subclinical atherogenesis in a group of children and adolescents affected by heFH in comparison to normo-lipidemic controls, and (b) to identify predictive factors influencing the endothelial function and its development in the same cohort of patients.
METHODS
This is a prospective, longitudinal and cross-sectional study. Physical examination, plasma lipid profile and brachial artery FMD were measured at baseline and after follow-up.
RESULTS
At baseline, FMD did not differ between heFH children (n.24, median age 9.71) and controls (n. 24, median age 10.29) (7.67 ± 9.26 vs. 11.18 ± 7.28 %, p 0.09). Nevertheless, during follow-up (median length of lipid-lowering diet 4.52 years), FMD got worse in 54% of heFH subjects and its worsening correlated to the increasing of low-density lipoprotein cholesterol (r -0.21, p < 0.05). Moreover, being male (β -0.46, p 0.03), undergoing puberty (β -0.61, p 0.03) and increasing of body mass index standard deviation score (β -0.39, p 0.03) were identified as main independent predictor factors of FMD drop.
CONCLUSIONS
During the first decades of life, not only hypercholesterolemia, but also clusters of pro-atherogenic conditions and their persistence, could affect the endothelial function and its trend. (www.actabiomedica.it).
Identifiants
pubmed: 34738580
doi: 10.23750/abm.v92i5.11074
pmc: PMC8689302
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2021343Références
Atherosclerosis. 2014 Aug;235(2):299-309
pubmed: 24908240
J Am Coll Cardiol. 2002 Jan 16;39(2):257-65
pubmed: 11788217
J Clin Invest. 1994 Jan;93(1):50-5
pubmed: 8282821
Atherosclerosis. 2011 Jan;214(1):129-38
pubmed: 21074770
N Engl J Med. 1998 Jun 4;338(23):1650-6
pubmed: 9614255
J Endocrinol Invest. 2007 Sep;30(8):700-19
pubmed: 17923804
J Clin Endocrinol Metab. 2014 Sep;99(9):3093-102
pubmed: 24848708
Circulation. 2000 Mar 7;101(9):948-54
pubmed: 10704159
Pediatr Int. 2008 Aug;50(4):447-53
pubmed: 19143965
Paediatr Drugs. 2014 Apr;16(2):105-14
pubmed: 24385386
Arterioscler Thromb Vasc Biol. 2000 Sep;20(9):E41-52
pubmed: 10978268
J Endocrinol Invest. 2006 Jul-Aug;29(7):581-93
pubmed: 16957405
JAMA. 1990 Dec 19;264(23):3018-24
pubmed: 2243430
Ann Hum Genet. 2012 Sep;76(5):387-401
pubmed: 22881376
Arch Dis Child. 1969 Jun;44(235):291-303
pubmed: 5785179
J Am Heart Assoc. 2014 Dec 02;3(6):e001236
pubmed: 25468658
Cochrane Database Syst Rev. 2014 Jun 10;(6):CD001918
pubmed: 24913720
Atherosclerosis. 2001 Aug;157(2):369-73
pubmed: 11472736
J Pediatr. 2016 Mar;170:199-205
pubmed: 26706233
Lancet. 1992 Nov 7;340(8828):1111-5
pubmed: 1359209
J Pediatr. 2009 Aug;155(2):199-204.e2
pubmed: 19446849
J Clin Invest. 1997 Dec 1;100(11):2680-90
pubmed: 9389731
Diabetes Res Clin Pract. 2006 May;72(2):155-61
pubmed: 16337304
J Pediatr Endocrinol Metab. 2015 Jan;28(1-2):125-31
pubmed: 25153571
Arterioscler Thromb Vasc Biol. 2000 Sep;20(9):2070-5
pubmed: 10978251
J Pediatr. 1998 Jul;133(1):35-40
pubmed: 9672507
Atherosclerosis. 2002 Jul;163(1):193-7
pubmed: 12048139
J Am Coll Cardiol. 2002 Dec 18;40(12):2117-21
pubmed: 12505222
J Lipid Res. 2013 Sep;54(9):2543-9
pubmed: 23833242
Mol Genet Metab. 2008 Mar;93(3):282-94
pubmed: 18023224
JAMA. 2004 Jul 21;292(3):331-7
pubmed: 15265847
Physiol Res. 2009;58(2):179-184
pubmed: 18380539
Pediatr Res. 2012 Sep;72(3):299-304
pubmed: 22785446
Circ Cardiovasc Imaging. 2010 Jan;3(1):8-14
pubmed: 19920030
Pediatrics. 2008 Jul;122(1):198-208
pubmed: 18596007
Kidney Int Suppl. 1999 Jul;71:S62-5
pubmed: 10412740
Curr Opin Cardiol. 2016 Jan;31(1):95-100
pubmed: 26599060
Pediatr Cardiol. 2014 Jan;35(1):63-70
pubmed: 23821294
Atherosclerosis. 2005 May;180(1):93-9
pubmed: 15823280
Atherosclerosis. 2010 Feb;208(2):437-41
pubmed: 19717150
Atherosclerosis. 2009 Jun;204(2):532-7
pubmed: 19004443